Galapagos NV (AMS:GLPG)
28.04
+0.12 (0.43%)
At close: Jan 7, 2026
Galapagos NV Revenue
Galapagos NV had revenue of 71.16M EUR in the quarter ending September 30, 2025, with 18.90% growth. This brings the company's revenue in the last twelve months to 286.92M, up 10.31% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm)
286.92M
Revenue Growth
+10.31%
P/S Ratio
6.41
Revenue / Employee
407.56K
Employees
704
Market Cap
1.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
| Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
| Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
| Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
| Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
| Dec 31, 2019 | 834.90M | 556.24M | 199.61% |
| Dec 31, 2018 | 278.67M | 151.58M | 119.27% |
| Dec 31, 2017 | 127.09M | -2.43M | -1.88% |
| Dec 31, 2016 | 129.52M | 89.96M | 227.37% |
| Dec 31, 2015 | 39.56M | -29.81M | -42.97% |
| Dec 31, 2014 | 69.37M | 69.29M | 90,429.20% |
| Dec 31, 2013 | 76.63K | -136.19M | -99.94% |
| Dec 31, 2012 | 136.27M | 42.80M | 45.79% |
| Dec 31, 2011 | 93.47M | -20.67M | -18.11% |
| Dec 31, 2010 | 114.14M | 21.05M | 22.62% |
| Dec 31, 2009 | 93.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGalapagos NV News
- 2 days ago - Galapagos (GLPG) to Cease Cell Therapy Operations - GuruFocus
- 2 days ago - Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities - GlobeNewsWire
- 16 days ago - Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation - Seeking Alpha
- 19 days ago - Galapagos (GLPG) Achieves Key Milestone in Dermatomyositis Study - GuruFocus
- 26 days ago - GLPG Crosses Above Average Analyst Target - Nasdaq
- 4 weeks ago - Galapagos (GLPG) Showcases Promising Phase 2 Results for CAR T-Cell Therapy - GuruFocus
- 4 weeks ago - Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025 - GlobeNewsWire
- 6 weeks ago - Galapagos Receives Transparency Notifications from Bank of America - GlobeNewsWire